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The CT20 peptide causes detachment and death of
metastatic breast cancer cells by promoting
mitochondrial aggregation and cytoskeletal disruption
MW Lee1,5, R Bassiouni2,5, NA Sparrow2, A Iketani2, RJ Boohaker2, C Moskowitz1, P Vishnubhotla3, AS Khaled3, J Oyer2, A Copik2,
C Fernandez-Valle2, JM Perez4 and AR Khaled*,2
Metastasis accounts for most deaths from breast cancer, driving the need for new therapeutics that can impede disease
progression. Rationally designed peptides that take advantage of cancer-specific differences in cellular physiology are an
emerging technology that offer promise as a treatment for metastatic breast cancer. We developed CT20p, a hydrophobic peptide
based on the C terminus of Bax that exhibits similarities with antimicrobial peptides, and previously reported that CT20p has
unique cytotoxic actions independent of full-length Bax. In this study, we identified the intracellular actions of CT20p which
precede cancer cell-specific detachment and death. Previously, we found that CT20p migrated in the heavy membrane fractions
of cancer cell lysates. Here, using MDA-MB-231 breast cancer cells, we demonstrated that CT20p localizes to the mitochondria,
leading to fusion-like aggregation and mitochondrial membrane hyperpolarization. As a result, the distribution and movement of
mitochondria in CT20p-treated MDA-MB-231 cells was markedly impaired, particularly in cell protrusions. In contrast, CT20p did
not associate with the mitochondria of normal breast epithelial MCF-10A cells, causing little change in the mitochondrial
membrane potential, morphology or localization. In MDA-MB-231 cells, CT20p triggered cell detachment that was preceded by
decreased levels of a5b1 integrins and reduced F-actin polymerization. Using folate-targeted nanoparticles to encapsulate and
deliver CT20p to murine tumors, we achieved significant tumor regression within days of peptide treatment. These results
suggest that CT20p has application in the treatment of metastatic disease as a cancer-specific therapeutic peptide that perturbs
mitochondrial morphology and movement ultimately culminating in disruption of the actin cytoskeleton, cell detachment, and
loss of cell viability.
Cell Death and Disease (2014) 5, e1249; doi:10.1038/cddis.2014.225; published online 22 May 2014
Subject Category: Experimental Medicine
Mitochondria are promising therapeutic targets given their role
in regulating metabolism, cell death, and powering cytoske-
letal changes involved in cell motility.1–4 Emerging evidence in
the literature indicates that the ability of breast cancer cells to
migrate and metastasize, which depends on cytoskeletal
changes, may be linked to mitochondrial morphology and
subcellular localization.5,6 Thus disrupting mitochondrial
function would not only impact energy production but also
impact cell adhesion and migration. What is lacking are new
therapeutic agents that modulate mitochondrial dynamics and
decrease the ability of this organelle to move and produce
localized amounts of ATP that drive cytoskeletal change.
Such an agent could effectively impair cancer cell invasion,
attenuating migration, and inducing the death of highly
metastatic cancer cells.
Therapeutic peptides that can target the mitochondria of
cancer cells and induce cell death hold significant promise
and may represent an avenue to restrain migration and
metastasis.7 Many cancer therapeutic peptides fall under the
umbrella of naturally occurring antimicrobial peptides that
form pores in membranes, facilitating the release of intra-
membrane contents.7,8 In mammalian systems, these
peptides are relatively inactive against the plasma membrane,
but if transfected or delivered into the cell, they exhibit
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pore-forming activity towards the prokaryotic-like membrane
of the mitochondria. Considerable effort has been expended
in developing synthetic peptides to trigger mitochondrial
membrane permeability changes and promote cytochrome
C release and apoptosis; however, these approaches do not
specifically harness differences between normal and cancer-
ous cells, which often harbor mutations in proteins that govern
apoptosis. An attractive alternative is to develop peptides from
endogenous mitochondrial-localized proteins with documen-
ted functions. Numerous examples of this strategy exist,
including the Nur77 peptide, VDAC-1 peptides, and more
recently peptides derived from Bax.9–13 Despite the advan-
tages of these approaches, many concerns remain, such as
bioavailability and off-target effects.
We previously reported that a peptide derived from the C
terminus of Bax, CT20p, had similarities to antimicrobial
peptides,11 forming pores in artificial lipid vesicles and
releasing intravesicular contents.14,15 When expressed in
cells, CT20p localized to the mitochondria, promoting cell
death, even in cells deficient in Bax, indicating that the peptide
functioned independently of the parent protein and potential
defects in the apoptotic machinery.11 However, the hydro-
phobic nature of CT20p, its inability to penetrate plasma cell
membranes, and general problems with peptide stability in
serum challenged the direct use of CT20p. An optimal solution
was encapsulation of CT20p in hyperbranched polymeric
nanoparticles (HBPE-NPs) that could be decorated with
targeting ligands to concentrate the peptide in tumors.11,16
CT20p-HBPE-NPs (henceforth referred to as CT20p) killed
colon and breast cancer cells, causing tumor regression in
mice.11 Nevertheless, the key intracellular actions of CT20p
that led to cell death remained unknown. Herein we report that
CT20p impairs mitochondrial movement and distribution and
has deleterious effects on integrins and F-actin polymeriza-
tion, causing cell detachment and death in a cancer-specific
manner. These findings suggest that CT20p could have
potential clinical use as a mitochondrial-targeting, antimeta-
static agent.
Results
CT20p localizes to mitochondria in breast cancer cells
and causes cell death. As we previously reported, treat-
ment conditions and cell viability are routinely assessed with
each batch of nanoparticles, loaded with CT20p, by
measuring percent death (indicated by increased membrane
asymmetry), to establish the concentration that killsB50% of
cancer cells in 48 h.11 This is B3.5–4.0 nM CT20p or
75–100mg nanoparticles/ml (Supplementary Figures 1A and B),
which was the dose used for all experiments performed. In
Figure 1a, using the metastatic breast cancer cell line, MDA-
MB-231, and the breast epithelial cell line, MCF-10A, a time-
course assessment of death after CT20p treatment is shown.
No markers of late apoptotic or necrotic cell death were
detected at 3 or 6 h post CT20p treatment in MDA-MB-231 or
MCF-10A cells. We then confirmed our previous findings that
death of MDA-MB-231 cells, indicated by changes in plasma
membrane symmetry and permeability, was detectable
24–48 h after CT20p treatment. In contrast, MCF-10A cells
were more resistant to the cytotoxic effects of CT20p at all
the time points examined (Figure 1a). Hence, the intramo-
lecular events that underlie the cancer-specific cell death
induced by CT20p likely occur within the first few hours of
treatment before cells display characteristic features of cell
death. The cytotoxic effects of CT20p were not cell line
specific because we observed a similar cancer-specific
killing trend using freshly isolated breast tumor cells and
normal breast epithelial cells from a breast cancer patient.
In Figure 1b, we show that CT20p killedB47% of the breast
tumor cells by 48 h, buto10% of the normal breast epithelial
cells.
To track the intracellular localization of CT20p, we labeled
the N terminus of the peptide with rhodamine (RHO) and
encapsulated RHO-CT20p in HBPE-NPs. Previously, we
detected CT20p in mitochondrial-enriched cell fractions.11
To examine the association of CT20p with intracellular
organelles, we stained cells with Mitotracker Green or
ER-Tracker Green. Live cell confocal microscopy enabled
the detection of colocalized RHO-CT20p (red fluorescence)
with organelles (green fluorescence). In MDA-MB-231 and
MCF-10A cells, internalization of RHO-CT20p was observed
within 1 hour, and visualization of total red fluorescence
indicated that uptake was equivalent (Figure 2a and
Supplementary Figure 2). Colocalization of RHO-CT20p with
mitochondria was detected between 1–3 h in MDA-MB-231
cells but not in MCF-10A cells (Figure 2a). CT20p did not
colocalize with the endoplasmic reticulum in either cell type
(Figure 2b and Supplementary Figure 2B). Quantitation
(Pearson’s coefficient (PC)) of the colocalization of CT20p
with organelles was based on correlating the strength
of the linear relationship between the red and green
fluorescent channels. CT20p associated with mitochondria
in MDA-MB-231 cells (PC¼ 0.909) but less so in MCF-10A
cells (PC¼ 0.136) (Figure 2c). Z-planes from the composite
images in Figure 2 are shown in Supplementary data
(Supplementary Figures 2A and B). These results suggest
that the initial association of CT20p with mitochondria may
depend on inherent metabolic or morphological differences
that are unique to breast cancer cells.
To examine changes in mitochondrial morphology and Dc
as a consequence of CT20p treatment, we used the
mitochondrial-specific dye, JC-1. The monomeric form of
JC-1 in the cytosol fluoresces green, whereas mitochondrial-
associated JC-1 fluoresces red, with its intensity dependent
on the Dc. MDA-MB-231 and MCF-10A cells, treated with
CT20p for 0 and 3 h, were stained with JC-1, and fluorescence
was analyzed by flow cytometry. At the 3 h time point,
MDA-MB-231 cells, in contrast to MCF-10A cells, exhibited
marked Dc hyperpolarization upon CT20p treatment
(Figure 2d). These results were confirmed by confocal
microscopy (Figure 2e). Moreover, CT20p altered the
distribution of mitochondria in MDA-MB-231 cells but not in
MCF-10A cells, causing significant clustering of mitochondria
(Figure 2e).
CT20p promotes the fusion-like aggregation of mito-
chondria. To investigate the nature of the mitochondrial
aggregation observed in CT20p-treated MDA-MB-231 cells
(Figure 2e), we next examined mitochondrial fusion, using
cells transfected with mitoDendra, and time-lapse, laser
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scanning confocal microscopy was performed.17 Photocon-
version of mitoDendra in a restricted region of the cell
generated red mitochondria that were monitored over time
for fusion with unconverted green mitochondria. In Figure 3a,
a schematic shows the experimental design. Images were
captured at 120 min and 180 min, encompassing a CT20p
treatment window from 1–1/2 to 3 h. As shown in Figure 3b,
mitochondria in control MDA-MB-231 cells did not fuse in the
time interval observed. Note that in the DIC image, green
fluorescent mitochondria in control MDA-MB-231 cells were
distributed throughout the cell, especially at the extensions or
protrusions (Figure 3b), and cell movement (see arrows) was
captured, highlighting the heightened motility of these cells.
In MDA-MB-231 cells treated with CT20p, fusion of red and
green mitochondria was visible as indicated by the appear-
ance of yellow fluorescence (Figure 3c). The DIC images of
CT20p-treated MDA-MB-231 cells revealed the aggregation
of green fluorescent mitochondria (Figure 3c) that was
previously observed upon JC-1 staining (Figure 2e). In
control or CT20p-treated MCF-10A cells, which are flatter
cells, no mitochondrial fusion was detected (Figures 3d and e).
DIC images verify cell attachment throughout imaging.
Additional controls, not shown, included the use of an
irrelevant peptide that resulted in outcomes similar to the
untreated controls.
To determine whether CT20p affected mitochondrial fusion
proteins, the mitochondrial localization of mitofusin 2
(MFN2)18,19 and optic atrophy 1 (OPA1)20 were examined
by immunoblot (Figures 3f and g). In MDA-MB-231 cells,
MFN2 and OPA1 increased following 3 h of treatment with
CT20p (Figure 3f) and coincided with the time points at which
mitochondrial fusion was observed (Figure 3c). In contrast,
mitochondrial-localized MFN2 was undetectable in CT20p-
treated or untreated MCF-10A cells, and only a slight increase
in OPA1 occurred (Figure 3g). Previously, others had shown
that overexpression of MFN2 caused mitochondrial clustering
and cell death.21 To determine whether overexpressing MFN2
could mimic the effects of CT20p, we transiently transfected
cells with MFN2-YFP. Cells were also stained with Mitotracker
Red. Overexpression of MFN2-YFP in MDA-MB-231 and
MCF-10A cells caused membrane blebbing and morphologi-
cal changes associated with cell death (Supplementary
Figure 3A and Supplementary movies). Moreover, blocking
fission with Mdivi-1,22 a small molecule inhibitor of the fission
protein Drp1, in MDA-MB-231 cells, caused similar effects on
mitochondria clustering, followed by mitochondrial depolar-
ization and cell death (Supplementary Figure 3B). Based on
these results, perturbing the mitochondrial fission/fusion
machinery in cancer cells may represent a viable means for
triggering cell death that could, in part, account, for the actions
of CT20p.
CT20p impairs mitochondrial distribution. Referring to
the DIC images in Figure 3c, CT20p-treated MDA-MB-231
cells exhibited a rounded morphology with decreased
membrane protrusions. Closer examination of mitochondrial
Figure 1 CT20p causes breast cancer cell-specific death. (a) MDA-MB-231 cells and MCF-10A cells were treated with CT20p, delivered in nanoparticles as described in
Materials and Methods, for the indicated time points. Cells were stained with Sytox AADvanced and F2N12S dyes, and cell viability was assessed by flow cytometry. Three cell
populations are identified and denoted as V (viable), A (apoptotic), and N (necrotic). Percentages of viable cells (black) and combined apoptotic/necrotic cells (red) are shown.
(b) Normal breast epithelial cells and primary breast tumor cells were isolated as described in the Materials and Methods, treated with CT20p and cell viability examined as
described above
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distribution in CT20p-treated MDA-MB-231 cells by confocal
microscopy at 2 h post treatment revealed the retraction
of mitochondria (stained by MitoTracker Green) from
membrane ruffles/protrusions (Figure 4a). In contrast,
mitochondria in MCF-10A cells were localized throughout
the cell, even after CT20p treatment (Figure 4b). A possible
explanation for the altered mitochondrial distribution in
CT20p-treated cells is that the peptide was impairing
mitochondrial movement. To examine this, cells treated with
CT20p were stained with MitoTracker Green and time-lapse
images of mitochondrial movement were obtained. The
velocity of mitochondrial movement was determined by
tracking individual mitochondria using post-analysis
software. This analysis indicated that the mitochondria of
MDA-MB-231 cells were moving faster than the mitochondria
of MCF-10A cells, and that mitochondrial movement was
reduced by CT20p treatment (Figure 4c: see arrows).
Calculation of average mitochondrial velocities under each
condition revealed that CT20p caused a fourfold decrease in
mitochondrial velocity in MDA-MB-231 cells as compared
with control cells (Figure 4d).
As CT20p treatment significantly impacted mitochondrial
movement, we next examined mitochondrial bioenergetics.
Cellular ATP levels were measured 3 h post CT20p treatment
and a decrease upon CT20p treatment in MDA-MB-231 cells
but not MCF-10A cells was noted in comparison with
untreated cells or control nanoparticles (Figures 4e and f).
Next, we examined the effect of CT20p upon oxygen
consumption and mitochondrial coupling efficiency at the time
points that we observed mitochondrial clustering (3–6 h post
CT20p treatment). Whereas we observed inherent differ-
ences in mitochondrial respiration and coupling efficiency
between MDA-MB-231 and MCF-10A cells, CT20p had little
to no effect on these processes (Figure 4g). As the
mitochondrial respiration machinery seemed unperturbed by
CT20p at the time points examined, localized loss of ATP
owing to mitochondrial aggregation or extracellular release
could account for decreased ATP levels (Figure 4e). As it was
possible that mitochondrial fusion could alter cytoskeletal
dynamics,6 we then sought to determine if the action of CT20p
upon mitochondria could lead to loss of cell adhesion and
deregulate the cytoskeleton.
CT20p disrupts cell attachment and cytoskeletal
organization. Localization of mitochondria to cell protrusions
is critical for cancer cell migration.6,23 Loss of mitochondria
Figure 2 CT20p localizes to the mitochondria and increases the mitochondrial membrane potential in breast cancer cells. (a, b) MDA-MB-231 and MCF-10A cells were
treated with RHO-labeled CT20p (RHO-CT20p), delivered in nanoparticles as described in Materials and Methods, stained with Mitotracker green (a) or ER-tracker green (b)
for the indicated times, and analyzed by live cell imaging. Colocalization is denoted by yellow fluorescence. Scale shown is 25 mM (MDA-MB-231) and 10mM (MCF-10A). Inset
magnification scale is 5 mM. (c) Colocalization coefficients of RHO-CT20p were calculated from the data in (a) and (b). *P40.05. (d, e) MDA-MB-231 and MCF-10A cells were
treated with CT20p as in (a, b), stained with the mitochondrial permeable dye, JC-1, and analyzed by flow cytometry (d) and confocal microscopy (e). H, high; M, mid; and L,
low indicate mitochondrial membrane potential. Scale shown is 10 mM
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redistribution to these regions following CT20p treatment
could have detrimental consequences on cell attachment,
which we examined using a crystal violet-based cellular
adhesion assay. Briefly, cells were seeded to dishes coated
with fibronectin, followed by treatment with CT20p.20 In
contrast to the CT20p-treated MCF-10A cells that remained
attached, MDA-MB-231 cells detached from the substrate by
6 h of CT20p treatment (Figures 5a and b). Subsequent
iterations of this experiment with either uncoated plates or
control nanoparticles revealed similar results. Based on
these observations, we next determined whether CT20p-
mediated detachment of MDA-MB-231 cells was accompa-
nied by alterations in integrins that are aberrantly expressed
in breast cancer.24–27 Cells were treated with CT20p, and a5
and aV integrins were detected by immunoblot (Figure 5c),
whereas b1 and b3 integrins were assessed by flow
cytometry (Figure 5d). In MDA-MB-231, but not MCF-10A
cells, b1 decreased after 3 h of CT20p treatment, whereas
surface levels of b3 were not altered until after 24 h
(Figure 5d). As CT20p-treated MDA-MB-231 cells detached
by 6 h (Figure 5a), the early detection of reduced b1 integrin
was noteworthy. In MDA-MB-231 cells, but not MCF-10A
cells, expression of a5 integrin decreased after 3 and 6 h of
CT20p treatment (Figure 5c). The aV integrin also decreased
upon CT20p treatment in MDA-MB-231 cells but not in
MCF-10A cells. The decrease in a5 integrin expression
detected at 3 h post CT20p treatment (Figure 5c) mirrored
the decreased surface expression of b1 seen by flow
cytometry (Figure 5d), suggesting that the heterodimeric
a5b1 complex was being affected and could in part be
responsible for causing CT20p-mediated cell detachment.
Another consequence of reduced mitochondrial movement
induced by CT20p could be decreased actin polymerization.
Others have shown that mitochondrial redistribution was
Figure 3 CT20p causes fusion of mitochondria in breast cancer cells. (a) Experimental plan is shown in schematic. At time 0, cells expressing MitoDendra, a photo-
activatable mitochondrial targeted fluorescent protein to monitor fusion, were treated with CT20p, delivered in nanoparticles, as described in Materials and Methods. After
90 min, cells were photo-activated to produce red mitochondria and images were acquired 30 (120 min post CT20p treatment) and 60 min later (180 min post CT20p
treatment). Mitochondrial fusion was thus observed between 1–1/2 to 3 h post CT20p treatment. (b–e) MDA-MB-231 cells (b, c) or MCF-10A cells (d, e) were treated as
described in (a). The green represents unconverted mitoDendra, the red is photo-activated mitoDendra, and the yellow results from fusion of red and green mitochondria.
Arrows and inset indicate areas of photo-activation and movement of cells. Cells were untreated (CTRL) (b, d) or treated with CT20p (c, e) as described in (a) Representative
images were acquired from time-lapse movies taken over a 90-minute period. Scale shown is 20, 000 nM or 20 mM. The scaling of the images was adjusted in panel b to show
the movement of cells within a larger field of vision. Similar movement was not observed in MCF-10A cells or in MDA-MB-231 cells upon treatment with CT20p. (f, g)
Mitochondria lysates from MDA-MB-231 cells (f) and MCF-10A cells (g), treated with CT20p delivered in nanoparticles, were subjected to SDS-PAGE and immunoblotted for
fusion proteins, MFN2 and OPA1. Prohibitin is a loading control for mitochondrial proteins. Fold changes were determined by densitometry for each representative blot. Images
were cropped to improve presentation
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required for actin polymerization.6 To examine this, cells were
probed with Mitotracker Red, the F-actin-specific dye phalloi-
din-AF633 (pseudo-colored green), the nuclear stain DAPI
(blue) and imaged by confocal microscopy. CT20p treatment
for 3 and 6 h in MDA-MB-231 cells impaired mitochondrial
distribution and dramatically reduced the amount of F-actin
detected (Figure 6a). In control MDA-MB-231 cells (0 h), as
well as control and CT20p-treated MCF-10A cells, F-actin was
detectable (Figures 6a and b). F-actin levels were quantitated
and they revealed a general decrease in F-actin in
CT20p-treated MDA-MB-231 cells over time, with statistically
significant changes noted at the 6-h time point compared with
control cells (Figure 6c). No significant changes were noted in
the expression of beta-actin in either cell type (Figure 6d).
Therefore, we concluded that CT20p, in addition to its actions
on the mitochondria, inhibited the polymerization of actin
filaments in breast cancer cells but not in normal breast
epithelial cells.
CT20p causes breast cancer cell death in vitro and
in vivo. To continue our investigation into the cytotoxic
effects of CT20p, we examined the lethality of the peptide
under hypoxic conditions associated with tumor environ-
ments. Increased cell death of MDA-MB-231 cells that were
treated with CT20p for 48 h was detected under hypoxia-
mimicking conditions (Figure 7a), indicating that the
cytotoxicity of the peptide was likely unimpaired under
low-oxygen conditions.
Next, we assessed the capacity of CT20p to act as a
therapeutic agent in vivo in a murine breast tumor model.
MDA-MB-231 cells were subcutaneously implanted in mice,
and tumor growth was measured. Groups of mice with tumors
(B5–8 mm2) were given two sets of intravenous injections of
CT20p over a 2-week period. Post-treatment tumor size was
monitored by ultrasound (every 2–3 days). Two different
HBPE-NPs were used for delivery of CT20p: untargeted
carboxylated (COOH) nanoparticles (used in in vitro experi-
ments) and folate-decorated (FOL) nanoparticles that target
cells expressing folate receptors, like MDA-MB-231 cells.27
From our previous studies, we knew that untargeted and
folate-targeted nanoparticles were equally effective in vitro;
however, we anticipated that the folate-targeted nanoparticles
Figure 4 Mitochondrial movement and velocity decreases with CT20p treatment in breast cancer cells. (a, b) MDA-MB-231 cells (a) or MCF-10A cells (b) were untreated
or treated with CT20p, delivered in nanoparticles as described in Materials and Methods, for 0-2 h and stained with Mitotracker green. Time-lapse movies were acquired at five
images/sec for 2 min. Representative endpoint images from movies are shown. (c) Digitally magnified images show mitochondria from representative images (a, b). Scale for
images is 12mM (a, b) and 6 mM (c). (d) Mitochondrial velocity calculations were made with Volocity software (Perkin Elmer) using data from (a, b). (e, f) Intracellular ATP
levels were measured in MDA-MB-231 cells (e) and MFC-10A cells (f) untreated (UNT), treated with CT20p as above or an irrelevant peptide (CTRL) for 3 h. *P40.05.
(g, h) MDA-MB-231 or MCF-10A cells were untreated or treated with CT20p as above for 3 h at which point (see red arrow) mitochondrial stress analysis was performed using
the Seahorse XFe24 analyzer. Oxygen consumption (g) and mitochondrial coupling efficiency (h) were determined following timed additions of inhibitors as described in
Materials and Methods. Assay time wasB2 h, for a total CT20p treatment time ofB5 h
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would concentrate more effectively in tumors when introduced
intravenously. Further, to improve circulation and prevent
uptake by the reticuloendothelial system, nanoparticles were
pegylated, which did not impair uptake by cells as shown
using nanoparticles loaded with a dye (Supplementary
Figure 4A). Mice were treated twice with HBPE-NPs and the
net change in tumor size, determined during a 14-day period
for each group of mice, is shown in Figure 7b. When CT20p
was delivered in COOH-NPs, tumor growth was inhibited.
When delivered in FOL-NPs, CT20p caused significant tumor
regression, with little to no tumor detected after 14 days. In
contrast, tumors continued to grow in mice receiving only PBS
or HBPE-NPs with an irrelevant peptide. As a positive control,
mice received FOL-targeted doxorubicin (DOX). CT20p
proved as effective if not better than DOX, an established
agent employed in breast cancer chemotherapy. Hematoxylin
& eosin (H & E) stained sections of the liver and spleen
(where untargeted HBPE-NPs could accumulate) from
CT20p-treated mice were evaluated by a pathologist and
found to have no overt signs of necrosis or damage, whereas
targeted tumor tissue did display areas of necrosis
(Supplementary Figure 4B). In a representative experiment
shown in Figures 7c and d, we display ultrasound images from
three mice in which the tumor’s growth was monitored forB1
month. During this time, one mouse, whose tumor was
B8 mm2 after two weeks, was treated with FOL-CT20p twice,
whereas another mouse was treated with FOL-CT20p in a
similar manner but the tumor had grown for 1 week and was
B1.5 mm2. In both instances, CT20p impaired tumor growth
indicating that its activity could be independent of tumor size,
although it should be noted that tumor vascularity can affect
intravenous delivery of drugs. Although preliminary, these
results indicate that CT20p encapsulated in nanoparticles can
be targeted to tumors and as such has promising use as an
anticancer agent.
Discussion
In our study, we describe a novel therapeutic peptide,
CT20p, which displays cancer-specific cytotoxic activity.
In susceptible cancer cells, CT20p localized to mito-
chondria and promoted fusion-like aggregation, mitochondrial
membrane hyperpolarization, and hindered mitochondrial
movement. Furthermore, CT20p reduced integrin expression
and impaired polymerization of the actin cytoskeletal prior
to cancer cell detachment and death. As a result, treatment of
mice bearing subcutaneous tumors with CT20p, delivered
in HBPE-NPs targeted to the folate receptor, led to
complete tumor regression. Therefore, CT20p, by disrupting
mitochondrial redistribution and the cytoskeleton, could limit
metastatic cancer cell movement and hasten the death of
these cells.
Figure 5 CT20p treatment reduces cell adhesion and integrin levels in breast cancer cells. (a, b) MDA-MB-231 (a) and MCF-10A (b) cells were untreated (CTRL) or
treated with CT20p, delivered in nanoparticles as described in Materials and Methods, and cell adhesion measured at time points indicated using a standard crystal violet
adhesion assay. *Po0.05. (c) Cell lysates from MDA-MB-231 and MCF-10A cells, treated with CT20p as above for 0, 3, 6, and 24 h, were immunoblotted for expression of a5
and aV integrins. p38 MAPK is shown as a loading control for whole-cell lysates. Fold changes refer to the representative blots shown. Images were cropped to improve
presentation. (d) MDA-MB-231 and MCF-10A cells, treated with CT20p as above for 0, 3 and 24 h, were analyzed for b1 (CD29) and b3 (CD61) integrins by flow cytometry
using fluorescently-tagged antibodies as described in Materials and Methods. Median peak values are shown in table
CT20 peptide causes death of metastatic cells
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Mitochondria are highly motile organelles, which possess
the capability to re-localize to subcellular regions of a cell
depending on local energy demands.4 Recent evidence
indicates that mitochondria in cancer cells are physiologically
different from non-transformed cells.6 As example, cancer cell
mitochondria preferentially rely on HSP90 chaperones to
maintain energy production during tumor progression and
metastasis.28 Two other studies suggested a role for dynamic
mitochondrial changes in the support of cancer cell motility.5,6
Silencing the expression of the fission protein Drp1 in MDA-
MB-231 and MDA-MB-436 cells caused mitochondria to
assume an elongated morphology and reduced the invasive-
ness of these cells.6 Further, the polarity of mitochondrial
localization in metastatic cells was associated with cell
directional movement, and the disruption of fusion and fission
interfered with mitochondrial localization and cell migration
velocity.5 Therefore, altering the fragmented mitochondrial
phenotype that may be a metabolic adaptation in metastatic
breast cancer cells could impair essential biological activities
upon which these cells rely. Indeed, deregulation of
mitochondrial fission can alter cell cycle progression, impair
mitochondrial function, and promote mitochondrial loss.29,30
There is precedent for the effect of CT20p upon mitochon-
drial physiology. A study of the soluble, monomeric form of
Bax revealed that it interacts with and regulates MFN2
homotypic complex formation, thus favoring mitochondrial
fusion.31 This fusion-inducing activity of Bax is separable from
the oligomerized form which inserts into the mitochondrial
membrane to induce apoptosis. How Bax interacts with MFN2
to regulate fusion and if a particular domain within Bax is
driving this interaction remains to be determined. It is possible
that the C terminus of Bax could exhibit similar actions
towards MFN2 as does the full-length protein given our
findings that CT20p promotes a fusion-like aggregation of
mitochondria that is accompanied by elevated levels of MFN2.
As an alternative explanation, existing literature suggests
that, by forming a pore, Bax could participate or favor
mitochondrial fusion.32 In previous studies of CT20p, we
found that the peptide formed pores in mitochondrial-like lipid
vesicles15 and, in this manner, enable the fusion or
Figure 6 Detection of F-actin is reduced upon CT20p treatment in breast cancer cells. (a, b) MDA-MB-231 cells (a) and MCF-10A cells (b) were treated with CT20p,
delivered in nanoparticles as described in Materials and Methods, for the times indicated. Cells were stained with Mitotracker red and then fixed and stained with DAPI (nucleus)
(blue) and Phalloidin for F-actin (pseudo-colored green) as described in Materials and Methods. Scale shown is 20 000 nM or 20mM and inset magnification scale is 5mM.
(c) Average F-actin per cell was determined as described in Materials and Methods. *Po0.05. (d) Cells above were treated with CT20p for 3 h and then Mitotracker red was
added. Cells were fixed and stained with DAPI (nucleus) (blue) and b-actin (total actin) (green). Images were visualized by fluorescent microscopy. Scale is 20 000 nm or 20mM
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aggregation of mitochondria. CT20p could also interfere
with the movement of cellular components on microtubules
and retard the transport of cargo, like mitochondria or
integrins.
The effective use of therapeutic peptides derived from
endogenous proteins is challenged by the lack of optimal
delivery strategies. In our studies, we capitalized on the
hydrophobic nature of CT20p and the use of HBPE-NPs that
can be conjugated to targeting ligands to guide them to
specific cell surface targets.16 The HBPE-NPs protected
CT20p while in circulation and allowed efficient uptake by
targeting tumor cells. Once taken up by cells, the peptide was
released from the nanoparticles and bound to mitochondria in
cancer cells as we have shown in our studies. Further, we
validated that CT20p affects the cytoskeleton, a ‘druggable
node’ for metastatic disease,33 in part by impairing mitochon-
drial redistribution to energy-demanding regions of the cell,
like cell protrusions. The next step to fully exploit the clinical
utility of CT20p, and is the focus of continuing studies, is
identifying the unique aspects of cancer cell mitochondria that
are targeted by the peptide.
Materials and Methods
Cell culture and reagents. MDA-MB-231 cells (ATCC HTB-26,
Manassas, VA, USA) were cultured in DMEM (Cellgro, Manassas, VA, USA)
with 10% fetal bovine serum and 1% penicillin–streptomycin. MCF-10A cells
(ATCC CRL-10317) were cultured in mammary epithelial cell growth media
(Lonza, Walkersville, MD, USA) with 1% penicillin–streptomycin. Cells were
authenticated by STR profiling (ATCC). CT20p (Ac-VTIFVAGVLTASLTIWKKMG-NH2)
and RHO-tagged CT20p were commercially synthesized (Biopeptide Co., Inc,
San Diego, CA, USA) at 498% purity. Human tissues were transported in
RPMI on ice. Upon receipt, tissues were washed thoroughly in PBS containing
1% penicillin–streptomycin and 5 mg/ml Fungizone (Life Technologies,
Carlsbad, CA, USA). Tissues were minced and digested in 0.1% collagenase I
(Gibco, Carlsbad, CA, USA) at 37 1C for 2 h. Differential centrifugation as
described by Speirs et al.34 was used to obtain an epithelial-enriched cell fraction.
Cells were maintained in mammary epithelial cell growth media (Lonza) at 37 1C
and 5% CO2. Human tissues were deidentified and the protocol for use was
approved by the Institutional Review Boards at the University of Central Florida
and Florida Hospital.
Figure 7 CT20p treatment impairs growth of breast tumors implanted in mice. (a) MDA-MB-231 cells were treated with CT20p under hypoxia-mimicking conditions as
described in Materials and Methods. After 48 h, cells were stained with Sytox AADvanced and F2N12S dyes, and cell viability was assessed by flow cytometry (see Figure 1a).
Populations are denoted as V (viable), A (apoptotic), and N (necrotic). Percentages of viable cells (black) and apoptotic/necrotic cells (red) are shown. (b) Mice (n¼ 5) with
subcutaneous tumors (MDA-MB-231 cells) were treated twice (afterB0 and 7 days from tumor detection) with PBS control, folate-receptor targeted doxorubicin (FOL-Dox),
folate-receptor targeted control nanoparticles with an irrevelant peptide (FOL-NP) or folate-receptor targeted CT20p nanoparticles (FOL-CT20p) over a 2-week period as
described in Materials and Methods. Non-targeted nanoparticles loaded with CT20p (COOH-CT20p) were also used. *Po0.05. (c) Representative ultrasound images from
mice treated with PBS, or FOL-CT20p acquired at experimental endpoints are shown. Tumor growth curves indicate the size of tumors and the times (arrows) of treatment over
a 36-day period
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CT20p-nanoparticle synthesis. CT20p was encapsulated into HBPE-NPs
following a previously reported method.11,16 In brief, 36ml of CT20p (0.05mg/ml)
solution in 250ml of DMSO were mixed in 250ml of a DMSO solution containing
the HBPE polymer (12 mg) for a ratio of B0.15mg peptide: 1 mg nanoparticles.
The resulting polymer/CT20p mixture in DMSO was added to deionized water
(2.5 ml) to form the HBPE (CT20p) NPs. The resulting NPs were purified using a
PD-10 column and dialyzed (MWCO 6-8K) against PBS (pH¼ 7.4). Dynamic light
scattering and zeta potential analysis of the nanoparticle reveals a size diameter of
88±2 nm and zeta potential of  54.5 mV. The HBPE-NPs (above) contain
functional carboxylic groups on their surface that results in a negative charge. For
targeting the folate receptor to concentrate the nanoparticles in murine tumors,
folic acid was conjugated to HBPE-NPs and nanoparticles pegylated as previously
described.35
Assays of cell viability. Short-term survival was assessed using the flow
cytometry based Sytox AADvanced and F2N12S Violet Ratiometric Apoptosis kit
according to the manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). Long-
term survival of cells was measured by clonogenic survival assay.36 The dose of
CT20p that killsB50% of the cells in 48 h was determined to beB3.5 nM (75mg
nanoparticles/ml) (Supplementary Figure 1). To induce hypoxia-mimicking
conditions, 200mM CoCl2 was added to the media.
Live cell imaging. Cells were plated in 35-mm glass-bottom dishes
(MatTek, Ashland, MA, USA) coated with 10 mg/ml fibronectin (Sigma,
Milwaukee, WI, USA) for MDA-MB-231 or 3.25 mg/cm2 Cell-Tak (BD
Biosciences, San Diego, CA, USA) for MCF-10A cells. Cells were treated with
CT20p and stained with 25 nM Mitotracker Green or 500 nM ER-Tracker Green
(Life Technologies). Images were acquired with a PerkinElmer UltraView
spinning disc confocal system, with AxioObserver.Z1 stand (Carl Zeiss,
Thornwood, NY, USA), in a humidity and temperature-controlled chamber
(LiveCell, Seoul, Korea). Time-lapse movies were acquired using a Plan-
Apochromat 63 Oil DIC objective. Images were processed with Volocity
software (PerkinElmer, Shelton, CT, USA). Live cell imaging was also used to
track mitochondrial movement and velocities calculated using the Volocity
software (PerkinElmer).
Detection of mitochondrial fusion. Cells, seeded in 24-well glass-
bottom dishes (MatTek), were transfected with mitoDendra17 using TransIT-LT1
transfection reagent (Mirus, Madison, WI, USA) according to the manufacturer’s
protocol and treated with CT20p. Live cell confocal imaging was performed using
Zeiss LSM 710 confocal microscope and ZEN 2010 software. Images were
obtained using a Zeiss 63 Plan-Apocromat oil immersion lens (numerical
aperture (NA¼ 1.4)), pinholes adjusted for an optical section thickness of 1 mm for
each channel, and a 488/543 dual dichroic. Photoconversion of mitoDendra was
achieved by exposing a region of interest within a cell to the 488 nm light from an
Argon laser set to 5 mW (20% power) with 5–20 iterations (depending on the
mitoDendra expression levels) at a pixel dwell time of 1.27 ms. Non-
photoconverted mitoDendra was visualized by excitation at 488 nm (Argon laser
at 0.05 mW, 0.2% power) and emission light collected at 500–540 nm.
Photoconverted mitoDendra was visualized by excitation at 543 nm (HeNe543
laser at 0.13 mW, 10% power) and emission light collected at 555-700 nm.
Fluorescence for the non- and photoconverted mitoDendra were captured
separately, whereas DIC images were captured simultaneously. Maximum
intensity projections were created and the resulting single z-slice movies were
optimized using ZEN 2010 software. MFN2 overexpression was performed using
pMFN-2-YFP (Addgene, Cambridge, MA, USA) and cells transfected as described
above.
Measurement of mitochondrial bioenergetics. Culture plates for use
in the Seahorse XFe24 analyzer were coated with Cell-Tak (BD Bioscience) at
3.5mg/cm2 and cells seeded at 60 000 cells/well. Oxygen consumption rates were
measured following the manufacturer’s protocol. For metabolic profiling, injections
of oligomycin (1 mM), FCCP (0.3mM), rotenone (0.1mM), and antimycin A (2 mM)
were used. The mitochondrial coupling efficiency was calculated as: % coupling
efficiency¼ (1 (minimum oligomycin response/final basal measurement)) 100.
To measure ATP, cells were treated with CT20p and total cellular ATP determined
using the ATPlite luminescence-based kit (PerkinElmer) according to the
manufacturer’s protocol. Luminescence was read with an Envision plate reader
(Perkin Elmer).
Detection of actin polymerization. Immunohistochemistry was performed
as previously described.36,37 For detection of total actin levels, cells were incubated
with a beta-actin primary antibody (Cell Signaling, Danvers, MA, USA) followed by
incubation with an AlexaFluor546 conjugated goat anti-mouse secondary antibody
(Invitrogen). For detection of F-actin and DNA, cells were stained with
AlexaFluorH633-phalloidin and DAPI (Invitrogen). Cells were visualized with a
Zeiss LSM 710 microscope. Images shown in figures were obtained using a Zeiss
63 Plan-Apocromat oil immersion lens, whereas images acquired for F-actin
quantification were obtained using a Zeiss 40 Plan-Apocromat oil immersion
lens. To determine the average F-actin levels per cell, the number of pixels above
background intensity was quantitated and then divided by the number of cells in
the image (Volocity software, Perkin Elmer). At least three images, containing
9–29 cells, per condition were quantified.
Measurement of mitochondrial membrane potential. The mito-
chondrial membrane potential (Dc) was measured by flow cytometry (488 nm
excitation and 530 nm (green)/585 nm (red) emission) using the dye JC-1 at a final
concentration of 1 mM (Life Technologies). For live cell imaging, cells were seeded
on glass, treated with CT20p, and stained with 1 uM JC-1, and imaged on the
Ultraview spinning disk confocal microscope (PerkinElmer) as described above.
Detection of proteins by western blot. Mitochondrial fractionation was
performed as previously described.38 Mitochondrial lysates or whole-cell lysates
were subjected to SDS-PAGE, transferred to Immobilon-FL membranes
(Millipore, Temecula, CA, USA) or PVDF membranes and probed with primary
antibodies against MFN2 (Millipore), OPA1 (Novus Biologicals, Saint Charles,
MO, USA), integrin a5 (Cell Signaling), integrin aV (Cell Signaling), and
prohibitin (Abcam, Cambridge, MA, USA) or p38 MAPK (Santa Cruz, Dallas, TX,
USA). Fluorescent detection was achieved by incubation with an IRDye 800CW
anti-mouse or anti-rabbit secondary antibody, followed by imaging with an
Odyssey detection system (LI-COR). Densitometry was analyzed using ImageJ
software.
Cellular adhesion assay. A standard crystal violet adhesion assay
was performed as previously described.39 Plates were uncoated or coated
with 20mg/ml fibronectin (Sigma), and cells were seeded at a density of
25 000 cells/well. Following treatment with peptides at time points indicated in the
figure, cells were fixed and stained with 5 mg/ml crystal violet. Absorbance at
595 nm was read on an EnVision plate reader (Perkin Elmer).
Measurement of cell surface integrin expression. Cells, treated with
CT20p, were washed with 5% FBS in PBS and stained with FITC mouse anti-
human CD61, PE mouse anti-human CD29 (BD Bioscience), or a corresponding
isotype control antibody (BD Bioscience). Data were acquired with an Accuri C6
flow cytometer and analyzed with FCS Express (Denovo, Niwot, CO, USA)
software.
In vivo studies. Female, 6–8-week-old, Foxn1nu/Foxn1nu nude mice
(Charles River, Troy, NY, USA) received subcutaneous injections of B106
MDA-MB-231 cells. Tumors were detected by ultrasound (VisualSonics Vevo
2100, Toronto, ON, Canada). Mice bearing tumors (B1.5–8 mm2) received tail
vain injections of 5 mg HBPE-NPs (untargeted or folate-receptor targeted)
encapsulating CT20p, or control nanoparticles as described in the figure. Folate-
targeted doxorubicin was used as a positive control. Two injections, after 0 and 7
days, were administered to each mouse in each group over a 2-week period, and
tumor size was monitored by ultrasound. For tissue staining, a standard
hematoxylin & eosin protocol was performed. An animal study protocol was
approved by the Institutional Animal Care and Use Committee at the University of
Central Florida.
Statistical analysis. For each figure, representative experiments are shown
that were replicated a minimum of three times. For microscopy, multiple fields
were acquired for each representative image. Two-way ANOVA was used to
compare different agents and different time points within each experiment with a
statistically significant difference defined as a P-value ofo0.05. Calculations were
performed with Prism (GraphPad, La Jolla, CA, USA). For the mouse studies,
given the size of the S.D. of the tumors and the difference in the means between
groups of control and treated mice, at a minimum of n¼ 5 for each group, at 95%
power the P-values were o0.05.
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